Switching from aflibercept to ranibizumab biosimilars maintains stability in nAMD treatment, offering a cost-effective ...
Clinical Trials in Cancer Cachexia, Inflammatory Bowel Disease and Retinal Disorders are Planned MONTVALE, N. J., Jan. 07, 2026 (GLOBE ...
Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets –– Pivotal Phase 3 trials in ...
Its distinctive occlusive texture is closer to a balm, which according to reviewers, can be more hydrating compared to other ...
A custom 30 G needle with a closed tip and side port shows equivalent performance to standard needles for anti-VEGF delivery.
Find out how higher dose aflibercept may reduce injection burden while preserving vision in retinal vasculopathy.
An overview of the top 10 stories from Optometry Times in 2025.
The most-read ophthalmology biosimilar stories of 2025 included FDA approvals and real-world data. The continued expansion of ...
Big Machine Racing announced today that retina surgeon and stock car driver Dr. Patrick Staropoli will join the team full time in the O’Reilly Auto Parts Series, beginning with the season opener at ...
W hen diagnosed with diabetic macular edema (DME) in 2017, Sarah Castaneda, 41, thought she would lose her eyesight completely. At least, that’s what her doctor told her would happen if she didn’t ...
On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ: REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following ...
First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback